An excitatory synapse hypothesis of depression

Trends in Neurosciences

Volumn 38, Issue 5, 2015, Pages 279-294

  Thompson, Scott M ^a   Kallarackal, Angy J ^a   Kvarta, Mark D ^a   Van Dyke, Adam M ^a   LeGates, Tara A ^a   Cai, Xiang ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glutamate; Hippocampus; Ketamine; Nucleus accumbens; Reward; Stress

Indexed keywords

CHLORPHENIRAMINE MALEATE PLUS PHENYLEPHRINE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SCOPOLAMINE; SEROTONIN UPTAKE INHIBITOR; ANTIDEPRESSANT AGENT;

AMYGDALOID NUCLEUS; BRAIN DEPTH STIMULATION; CHRONIC STRESS; DEPRESSION; ELECTROCONVULSIVE THERAPY; EXCITATORY SYNAPSE; GENETIC SUSCEPTIBILITY; HABENULA; HIPPOCAMPUS; HUMAN; LATERAL HABENULA; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SYNAPSE; ANIMAL; BRAIN; DRUG EFFECTS; EXCITATORY POSTSYNAPTIC POTENTIAL; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSION; EXCITATORY POSTSYNAPTIC POTENTIALS; HUMANS; SYNAPSES;

EID: 84928415582     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2015.03.003     Document Type: Review

References (197)

1. Kessler R.C., et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 2005, 62:593-602.
2. Belmaker R.H., Agam G. Major depressive disorder. N. Engl. J. Med. 2008, 358:55-68.
3. Centers for Disease Control and Prevention Suicide Facts at a Glance 2009, Centers for Disease Control and Prevention.
4. Gartlehner G., et al. Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review 2011, Agency for Healthcare Research and Quality.
5. Gaynes B., Warden D. What did STAR* D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr. Serv. 2009, 60:1439-1445.
6. Duman R.S., Aghajanian G.K. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012, 338:68-72.
7. Nestler E., et al. Neurobiology of depression. Neuron 2002, 34:13-25.
8. Flint J., Kendler K.S. The genetics of major depression. Neuron 2014, 81:484-503.
9. Kendler K. Anna-Monika-Prize paper. Major depression and the environment: a psychiatric genetic perspective. Pharmacopsychiatry 1998, 31:5-9.
10. Billings A.G., et al. Social-environmental factors in unipolar depression: comparisons of depressed patients and nondepressed controls. J. Abnorm. Psychol. 1983, 92:119-133.
11. Korte S.M., et al. The Darwinian concept of stress: benefits of allostasis and costs of allostatic load and the trade-offs in health and disease. Neurosci. Biobehav. Rev. 2005, 29:3-38.
12. Sapolsky R.M. Why Zebras Don't Get Ulcers: A Guide to Stress, Stress Related Diseases, and Coping 1994, W.H. Freeman.
13. McEwen B.S. Allostasis and allostatic load: implications for neuropsychopharmacology. Neuropsychopharmacology 2000, 22:108-124.
14. Pariante C.M. Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids. Ann. N. Y. Acad. Sci. 2009, 1179:144-152.
15. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000, 23:477-501.
16. Anacker C., et al. The glucocorticoid receptor: pivot of depression and of antidepressant treatment?. Psychoneuroendocrinology 2011, 36:415-425.
17. Spijker A., van Rossum E. Glucocorticoid sensitivity in mood disorders. Neuroendocrinology 2012, 95:179-186.
18. Brown E.S. Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy. Ann. N. Y. Acad. Sci. 2009, 1179:41-55.
19. Frol A.B., et al. A comparison of clinician-rated neuropsychological and self-rated cognitive assessments in patients with asthma and rheumatologic disorders. Allergy asthma Proc. 2013, 34:170-175.
20. McEwen B.S. Brain on stress: how the social environment gets under the skin. Proc. Natl. Acad. Sci. U.S.A. 2012, 109(Suppl.):17180-17185.
21. Yun J., et al. Chronic restraint stress impairs neurogenesis and hippocampus-dependent fear memory in mice: possible involvement of a brain-specific transcription factor Npas4. J. Neurochem. 2010, 114:1840-1851.
22. Magariños A.M., McEwen B.S. Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: comparison of stressors. Neuroscience 1995, 69:83-88.
23. Fales C.L., et al. Antidepressant treatment normalizes hypoactivity in dorsolateral prefrontal cortex during emotional interference processing in major depression. J. Affect. Disord. 2009, 112:206-211.
24. Frodl T., et al. Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects. Biol. Psychiatry 2003, 53:338-344.
25. Lorenzetti V., et al. Structural brain abnormalities in major depressive disorder: a selective review of recent MRI studies. J. Affect. Disord. 2009, 117:1-17.
26. Pittenger C., Duman R.S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008, 33:88-109.
27. Sesack S.R., Grace A.a. Cortico-basal ganglia reward network: microcircuitry. Neuropsychopharmacology 2010, 35:27-47.
28. Smith K.S., et al. Disentangling pleasure from incentive salience and learning signals in brain reward circuitry. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:E255-E264.
29. Lim B.K., et al. Anhedonia requires MC4R-mediated synaptic adaptations in nucleus accumbens. Nature 2012, 487:183-189.
30. Bocklisch C., et al. Cocaine disinhibits dopamine neurons by potentiation of GABA transmission in the ventral tegmental area. Science 2013, 341:1521-1525.
31. Christoffel D.J., et al. IκB kinase regulates social defeat stress-induced synaptic and behavioral plasticity. J. Neurosci. 2011, 31:314-321.
32. Francis T.C., et al. Nucleus accumbens medium spiny neuron subtypes mediate depression-related outcomes to social defeat stress. Biol. Psychiatry 2015, 77:212-222.
33. Golden S.A., et al. Epigenetic regulation of RAC1 induces synaptic remodeling in stress disorders and depression. Nat. Med. 2013, 19:337-344.
34. Tye K.M., et al. Dopamine neurons modulate neural encoding and expression of depression-related behaviour. Nature 2013, 493:537-541.
35. Valenti O., et al. Different stressors produce excitation or inhibition of mesolimbic dopamine neuron activity: response alteration by stress pre-exposure. Eur. J. Neurosci. 2012, 35:1312-1321.
36. Belujon P., et al. Restoring mood balance in depression: ketamine reverses deficit in dopamine-dependent synaptic plasticity. Biol. Psychiatry 2014, 76:927-936.
37. Cabib S., Puglisi-Allegra S. The mesoaccumbens dopamine in coping with stress. Neurosci. Biobehav. Rev. 2012, 36:79-89.
38. Krishnan V., et al. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 2007, 131:391-404.
39. Cao J-L., et al. Mesolimbic dopamine neurons in the brain reward circuit mediate susceptibility to social defeat and antidepressant action. J. Neurosci. 2010, 30:16453-16458.
40. Barik J., et al. Chronic stress triggers social aversion via glucocorticoid receptor in dopaminoceptive neurons. Science 2013, 339:332-335.
41. Chaudhury D., et al. Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons. Nature 2013, 493:532-536.
42. Covington H.E., et al. Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex. J. Neurosci. 2010, 30:16082-16090.
43. Vialou V., et al. Prefrontal cortical circuit for depression- and anxiety-related behaviors mediated by cholecystokinin: role of δFosB. J. Neurosci. 2014, 34:3878-3887.
44. Amat J., et al. Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus. Nat. Neurosci. 2005, 8:365-371.
45. Berridge K.C., Kringelbach M.L. Neuroscience of affect: brain mechanisms of pleasure and displeasure. Curr. Opin. Neurobiol. 2013, 23:294-303.
46. Kennedy S.H., et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am. J. Psychiatry 2001, 158:899-905.
47. Liston C., et al. Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting. J. Neurosci. 2006, 26:7870-7874.
48. Radley J.J., et al. Repeated stress alters dendritic spine morphology in the rat medial prefrontal cortex. J. Comp. Neurol. 2008, 507:1141-1150.
49. Yuen E.Y., et al. Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex. Neuron 2012, 73:962-977.
50. Aghajanian G.K., Marek G.J. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 1997, 36:589-599.
51. Lambe E.K., et al. Serotonin induces EPSCs preferentially in layer V pyramidal neurons of the frontal cortex in the rat. Cereb. Cortex 2000, 10:974-980.
52. Béïque J-C., et al. Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:9870-9875.
53. Liu R-J., Aghajanian G.K. Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:359-364.
54. Matsumoto M., Hikosaka O. Lateral habenula as a source of negative reward signals in dopamine neurons. Nature 2007, 447:1111-1115.
55. Proulx C.D., et al. Reward processing by the lateral habenula in normal and depressive behaviors. Nat. Neurosci. 2014, 17:1146-1152.
56. Gonçalves L., et al. Differential projections from the lateral habenula to the rostromedial tegmental nucleus and ventral tegmental area in the rat. J. Comp. Neurol. 2012, 520:1278-1300.
57. Sego C., et al. Lateral habenula and the rostromedial tegmental nucleus innervate neurochemically distinct subdivisions of the dorsal raphe nucleus in the rat. J. Comp. Neurol. 2014, 522:1454-1484.
58. Christoph G.R., et al. Stimulation of the lateral habenula inhibits dopamine-containing neurons in the substantia nigra and ventral tegmental area of the rat. J. Neurosci. 1986, 6:613-619.
59. Matsumoto M., Hikosaka O. Representation of negative motivational value in the primate lateral habenula. Nat. Neurosci. 2009, 12:77-84.
60. Li B., et al. Synaptic potentiation onto habenula neurons in the learned helplessness model of depression. Nature 2011, 470:535-539.
61. Morris J.S., et al. Covariation of activity in habenula and dorsal raphé nuclei following tryptophan depletion. Neuroimage 1999, 10:163-172.
62. Duvarci S., Pare D. Amygdala microcircuits controlling learned fear. Neuron 2014, 82:966-980.
63. Drevets W.C. Neuroimaging abnormalities in the amygdala in mood disorders. Ann. N. Y. Acad. Sci. 2003, 985:420-444.
64. Vyas A., et al. Chronic stress induces contrasting patterns of dendritic remodeling in hippocampal and amygdaloid neurons. J. Neurosci. 2002, 22:6810-6818.
65. Felix-Ortiz A.C., Tye K.M. Amygdala inputs to the ventral hippocampus bidirectionally modulate social behavior. J. Neurosci. 2014, 34:586-595.
66. Magariños A.M., McEwen B.S. Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: involvement of glucocorticoid secretion and excitatory amino acid receptors. Neuroscience 1995, 69:89-98.
67. Pawlak R., et al. Tissue plasminogen activator and plasminogen mediate stress-induced decline of neuronal and cognitive functions in the mouse hippocampus. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:18201-18206.
68. Bartanusz V., et al. Stress-induced changes in messenger RNA levels of N-methyl-D-aspartate and AMPA receptor subunits in selected regions of the rat hippocampus and hypothalamus. Neuroscience 1995, 66:247-252.
69. Alfarez D.N., et al. Chronic unpredictable stress impairs long-term potentiation in rat hippocampal CA1 area and dentate gyrus in vitro. Eur. J. Neurosci. 2003, 17:1928-1934.
70. Schmidt M.V., et al. Individual stress vulnerability is predicted by short-term memory and AMPA receptor subunit ratio in the hippocampus. J. Neurosci. 2010, 30:16949-16958.
71. Kole M.H.P., et al. The antidepressant tianeptine persistently modulates glutamate receptor currents of the hippocampal CA3 commissural associational synapse in chronically stressed rats. Eur. J. Neurosci. 2002, 16:807-816.
72. Kallarackal A.J., et al. Chronic stress induces a selective decrease in AMPA receptor-mediated synaptic excitation at hippocampal temporoammonic-CA1 synapses. J. Neurosci. 2013, 33:15669-15674.
73. Remondes M., Schuman E.M. Role for a cortical input to hippocampal area CA1 in the consolidation of a long-term memory. Nature 2004, 431:699-703.
74. Freed W.J., et al. Properties of [3H]AMPA binding in postmortem human brain from psychotic subjects and controls: increases in caudate nucleus associated with suicide. Exp. Neurol. 1993, 121:48-56.
75. Meador-Woodruff J.H., et al. Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res. Bull. 2001, 55:631-640.
76. Cai X., et al. Local potentiation of excitatory synapses by serotonin and its alteration in rodent models of depression. Nat. Neurosci. 2013, 16:464-472.
77. Chourbaji S., et al. AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression. FASEB J. 2008, 22:3129-3134.
78. Auer D.P., et al. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol. Psychiatry 2000, 47:305-313.
79. Pfleiderer B., et al. Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatr. Res. 2003, 122:185-192.
80. Mitani H., et al. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:1155-1158.
81. Choudary P.V., et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:15653-15658.
82. Beneyto M., et al. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007, 32:1888-1902.
83. Nestler E.J., Carlezon W.A. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 2006, 59:1151-1159.
84. Akiskal H.S., McKinney W.T. Depressive disorders: toward a unified hypothesis. Science 1973, 182:20-29.
85. Leuner B., Shors T.J. Stress, anxiety, and dendritic spines: what are the connections?. Neuroscience 2013, 251:108-119.
86. Spijker J., et al. Predictors of suicidality in depressive spectrum disorders in the general population: results of the Netherlands Mental Health Survey and Incidence Study. Soc. Psychiatry Psychiatr. Epidemiol. 2010, 45:513-521.
87. Winer E.S., et al. Anhedonia predicts suicidal ideation in a large psychiatric inpatient sample. Psychiatry Res. 2014, 218:124-128.
88. Fawcett J., et al. Time-related predictors of suicide in major affective disorder. Am. J. Psychiatry 1990, 147:1189-1194.
89. Floresco S.B., et al. Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. J. Neurosci. 2001, 21:4915-4922.
90. Salamone J.D., Correa M. The mysterious motivational functions of mesolimbic dopamine. Neuron 2012, 76:470-485.
91. O'Donnell P., Grace A.A. Synaptic interactions among excitatory afferents to nucleus accumbens neurons: hippocampal gating of prefrontal cortical input. J. Neurosci. 1995, 15:3622-3639.
92. Legault M., et al. Chemical stimulation of the ventral hippocampus elevates nucleus accumbens dopamine by activating dopaminergic neurons of the ventral tegmental area. J. Neurosci. 2000, 20:1635-1642.
93. Tyler W.J., Pozzo-Miller L. Miniature synaptic transmission and BDNF modulate dendritic spine growth and form in rat CA1 neurones. J. Physiol. 2003, 553:497-509.
94. Sairanen M., et al. Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J. Neurosci. 2005, 25:1089-1094.
95. Weissbourd B., et al. Presynaptic partners of dorsal raphe serotonergic and GABAergic neurons. Neuron 2014, 83:645-662.
96. Malberg J.E., et al. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 2000, 20:9104-9110.
97. Gould E., et al. Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:3168-3171.
98. Sahay A., Hen R. Adult hippocampal neurogenesis in depression. Nat. Neurosci. 2007, 10:1110-1115.
99. Kobayashi K., et al. Chronic fluoxetine bidirectionally modulates potentiating effects of serotonin on the hippocampal mossy fiber synaptic transmission. J. Neurosci. 2008, 28:6272-6280.
100. Berman R.M., et al. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 2000, 47:351-354.
101. Zarate C.A., et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006, 63:856-864.
102. Garcia L.S.B., et al. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:140-144.
103. Li N., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
104. Li N., et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 2011, 69:754-761.
105. Moghaddam B., et al. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 1997, 17:2921-2927.
106. Homayoun H., Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci. 2007, 27:11496-11500.
107. Dwyer J.M., Duman R.S. Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants. Biol. Psychiatry 2013, 73:1189-1198.
108. Carlén M., et al. A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior. Mol. Psychiatry 2012, 17:537-548.
109. Kittelberger K., et al. Comparison of the effects of acute and chronic administration of ketamine on hippocampal oscillations: relevance for the NMDA receptor hypofunction model of schizophrenia. Brain Struct. Funct. 2012, 217:395-409.
110. Maksimow A., et al. Increase in high frequency EEG activity explains the poor performance of EEG spectral entropy monitor during S-ketamine anesthesia. Clin. Neurophysiol. 2006, 117:1660-1668.
111. Cornwell B.R., et al. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol. Psychiatry 2012, 72:555-561.
112. Lorrain D.S., et al. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003, 117:697-706.
113. Razoux F., et al. Ketamine, at a dose that disrupts motor behavior and latent inhibition, enhances prefrontal cortex synaptic efficacy and glutamate release in the nucleus accumbens. Neuropsychopharmacology 2007, 32:719-727.
114. Aan Het Rot M., et al. Ketamine for depression: where do we go from here?. Biol. Psychiatry 2012, 72:537-547.
115. Pozzi L., et al. Mice lacking NMDA receptors in parvalbumin neurons display normal depression-related behavior and response to antidepressant action of NMDAR antagonists. PLoS ONE 2014, 9:e83879.
116. Autry A.E., et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 475:91-95.
117. Nosyreva E., et al. Acute suppression of spontaneous neurotransmission drives synaptic potentiation. J. Neurosci. 2013, 33:6990-7002.
118. Maeng S., et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 2008, 63:349-352.
119. Kumar S., et al. Cortical control of affective networks. J. Neurosci. 2013, 33:1116-1129.
120. Furey M.L., Drevets W.C. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch. Gen. Psychiatry 2006, 63:1121-1129.
121. Voleti B., et al. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol. Psychiatry 2013, 74:742-749.
122. Li X., et al. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 2001, 40:1028-1033.
123. Farley S., et al. Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm. Int. J. Neuropsychopharmacol. 2010, 13:1207-1218.
124. Mackowiak M., et al. An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo study. Neuropharmacology 2002, 43:1-10.
125. Li X., et al. Enhancement of antidepressant potency by a potentiator of AMPA receptors. Cell. Mol. Neurobiol. 2003, 23:419-430.
126. Mayberg H.S., et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005, 45:651-660.
127. Hamani C., et al. Antidepressant-like effects of medial prefrontal cortex deep brain stimulation in rats. Biol. Psychiatry 2010, 67:117-124.
128. Malone D.A., et al. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol. Psychiatry 2009, 65:267-275.
129. Schlaepfer T.E., et al. Deep brain stimulation of the human reward system for major depression: rationale, outcomes and outlook. Neuropsychopharmacology 2014, 39:1303-1314.
130. Stewart C.A., et al. LTP-like synaptic efficacy changes following electroconvulsive stimulation. Neuroreport 1994, 5:1041-1044.
131. Stewart C.A., Reid I.C. Ketamine prevents ECS-induced synaptic enhancement in rat hippocampus. Neurosci. Lett. 1994, 178:11-14.
132. Naylor P., et al. Repeated ECS induces GluR1 mRNA but not NMDAR1A-G mRNA in the rat hippocampus. Brain Res. Mol. Brain Res. 1996, 35:349-353.
133. Fumagalli F., et al. Repeated electroconvulsive shock (ECS) alters the phosphorylation of glutamate receptor subunits in the rat hippocampus. Int. J. Neuropsychopharmacol. 2010, 13:1255-1260.
134. Nibuya M., et al. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J. Neurosci. 1995, 15:7539-7547.
135. Altar C.A., et al. Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol. Psychiatry 2003, 54:703-709.
136. Marshall E.F., et al. The effect of iproniazid and imipramine on the blood platelet 5-hydroxytrptamine level in man. Br. J. Pharmacol. Chemother. 1960, 15:35-41.
137. Woolley D.W., Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc. Natl. Acad. Sci. U.S.A. 1954, 40:228-231.
138. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry 1965, 122:509-522.
139. Lapin I.P., Oxenkrug G.F. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1969, 1:132-136.
140. Jacobsen J.P.R., et al. The 5-HT deficiency theory of depression: perspectives from a naturalistic 5-HT deficiency model, the tryptophan hydroxylase 2Arg439His knockin mouse. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2012, 367:2444-2459.
141. Mendels J., et al. Amine precursors and depression. Arch. Gen. Psychiatry 1975, 32:22-30.
142. Delgado P.L., et al. Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. Arch. Gen. Psychiatry 1994, 51:865-874.
143. Salomon R.M., et al. Lack of behavioral effects of monoamine depletion in healthy subjects. Biol. Psychiatry 1997, 41:58-64.
144. Moreno F.A., et al. Tryptophan depletion and depressive vulnerability. Biol. Psychiatry 1999, 46:498-505.
145. Guan X.M., McBride W.J. Fluoxetine increases the extracellular levels of serotonin in the nucleus accumbens. Brain Res. Bull. 1988, 21:43-46.
146. Cheetham S.C., et al. Brain 5-HT1 binding sites in depressed suicides. Psychopharmacology 1990, 102:544-548.
147. López-Figueroa A.L., et al. Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol. Psychiatry 2004, 55:225-233.
148. Savitz J.B., et al. 5-HT(1A) receptor function in major depressive disorder. Prog. Neurobiol. 2009, 88:17-31.
149. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 2006, 59:1116-1127.
150. Duman R.S., et al. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 1997, 54:597-606.
151. Chourbaji S., et al. Altering BDNF expression by genetics and/or environment: impact for emotional and depression-like behaviour in laboratory mice. Neurosci. Biobehav. Rev. 2011, 35:599-611.
152. Karege F., et al. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 2002, 109:143-148.
153. Shimizu E., et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol. Psychiatry 2003, 54:70-75.
154. Dwivedi Y., et al. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch. Gen. Psychiatry 2003, 60:804-815.
155. Chen B., et al. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol. Psychiatry 2001, 50:260-265.
156. Boldrini M., et al. Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology 2009, 34:2376-2389.
157. Jessen F., et al. No association of the Val66Met polymorphism of the brain-derived neurotrophic factor with hippocampal volume in major depression. Psychiatr. Genet. 2009, 19:99-101.
158. Schenkel L.C., et al. The BDNF Val66Met polymorphism is an independent risk factor for high lethality in suicide attempts of depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:940-944.
159. Verhagen M., et al. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol. Psychiatry 2010, 15:260-271.
160. Hajek T., et al. Reduced hippocampal volumes in healthy carriers of brain-derived neurotrophic factor Val66Met polymorphism: meta-analysis. world J. Biol. Psychiatry 2012, 13:178-187.
161. Zai C.C., et al. The brain-derived neurotrophic factor gene in suicidal behaviour: a meta-analysis. Int. J. Neuropsychopharmacol. 2012, 15:1037-1042.
162. Magariños A.M., et al. Effect of brain-derived neurotrophic factor haploinsufficiency on stress-induced remodeling of hippocampal neurons. Hippocampus 2011, 21:253-264.
163. Saarelainen T., et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J. Neurosci. 2003, 23:349-357.
164. MacQueen G.M., et al. Performance of heterozygous brain-derived neurotrophic factor knockout mice on behavioral analogues of anxiety, nociception, and depression. Behav. Neurosci. 2001, 115:1145-1153.
165. Chourbaji S., et al. Mice with reduced brain-derived neurotrophic factor expression show decreased choline acetyltransferase activity, but regular brain monoamine levels and unaltered emotional behavior. Brain Res. Mol. Brain Res. 2004, 121:28-36.
166. Chan J.P., et al. Examination of behavioral deficits triggered by targeting BDNF in fetal or postnatal brains of mice. Neuroscience 2006, 142:49-58.
167. Monteggia L.M., et al. Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biol. Psychiatry 2007, 61:187-197.
168. Pattwell S.S., et al. The BDNF Val66Met polymorphism impairs synaptic transmission and plasticity in the infralimbic medial prefrontal cortex. J. Neurosci. 2012, 32:2410-2421.
169. Berton O., et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006, 311:864-868.
170. Nowak G., et al. Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res. 1995, 675:157-164.
171. Caspi A., et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386-389.
172. Hosang G.M., et al. Interaction between stress and the BDNF Val66Met polymorphism in depression: a systematic review and meta-analysis. BMC Med. 2014, 12:7.
173. Sen S., et al. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry 2008, 64:527-532.
174. Albert P.R., Le François B. Modifying 5-HT1A receptor gene expression as a new target for antidepressant therapy. Front. Neurosci. 2010, 4:35.
175. Deschwanden A., et al. Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. Am. J. Psychiatry 2011, 168:727-734.
176. Duric V., et al. Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects. Int. J. Neuropsychopharmacol. 2013, 16:69-82.
177. Shrestha S., et al. Serotonin-1A receptors in major depression quantified using PET: controversies, confounds, and recommendations. Neuroimage 2012, 59:3243-3251.
178. Stamatakis A.M., Stuber G.D. Activation of lateral habenula inputs to the ventral midbrain promotes behavioral avoidance. Nat. Neurosci. 2012, 15:1105-1107.
179. Yatham L.N., et al. Effect of electroconvulsive therapy on brain 5-HT(2) receptors in major depression. Br. J. Psychiatry 2010, 196:474-479.
180. Smith D.F., Jakobsen S. Molecular neurobiology of depression: PET findings on the elusive correlation with symptom severity. Front. Psychiatry 2013, 4:8.
181. Meyer J.H., et al. Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch. Gen. Psychiatry 2009, 66:1304-1312.
182. Fitzgerald P.B., et al. A meta-analytic study of changes in brain activation in depression. Hum. Brain Mapp. 2008, 29:683-695.
183. Wang L., et al. Interhemispheric functional connectivity and its relationships with clinical characteristics in major depressive disorder: a resting state fMRI study. PLoS ONE 2013, 8:e60191.
184. Drevets W.C., et al. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur. Neuropsychopharmacol. 2002, 12:527-544.
185. Mies G.W., et al. Neurophysiological correlates of anhedonia in feedback processing. Front. Hum. Neurosci. 2013, 7:96.
186. Townsend J.D., et al. fMRI activation in the amygdala and the orbitofrontal cortex in unmedicated subjects with major depressive disorder. Psychiatry Res. 2010, 183:209-217.
187. Watanabe Y., et al. Stress induces atrophy of apical dendrites of hippocampal CA3 pyramidal neurons. Brain Res. 1992, 588:341-345.
188. Sousa N., et al. Reorganization of the morphology of hippocampal neurites and synapses after stress-induced damage correlates with behavioral improvement. Neuroscience 2000, 97:253-266.
189. Conrad C.D., et al. Chronic stress impairs rat spatial memory on the Y maze, and this effect is blocked by tianeptine pretreatment. Behav. Neurosci. 1996, 110:1321-1334.
190. Joëls M., Baram T.Z. The neuro-symphony of stress. Nat. Rev. Neurosci. 2009, 10:459-466.
191. Gourley S.L., Taylor J.R. Recapitulation and reversal of a persistent depression-like syndrome in rodents. Curr. Protoc. Neurosci. 2009, 9. 9.32.
192. Mathur B.N., et al. Serotonin induces long-term depression at corticostriatal synapses. J. Neurosci. 2011, 31:7402-7411.
193. Dölen G., et al. Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin. Nature 2013, 501:179-184.
194. Pascoli V., et al. Reversal of cocaine-evoked synaptic potentiation resets drug-induced adaptive behaviour. Nature 2012, 481:71-75.
195. Chen B.T., et al. Cocaine but not natural reward self-administration nor passive cocaine infusion produces persistent LTP in the VTA. Neuron 2008, 59:288-297.
196. Sanacora G., et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol. Psychiatry 2014, 19:978-985.
197. Murrough J.W., et al. Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder. Psychopharmacology 2011, 213:547-553.